Bringing science and development together through news and analysis

  • Vaccinating against 'Cantonese cancer'


Scientists in China will soon launch the first clinical trial of a vaccine to prevent nasopharyngeal cancer (NPC).

NPC, which affects around 40,000 people in China each year, has a five-year survival rate of less than 50 per cent. It is particularly prevalent in China's Cantonese-speaking Guangdong Province and the Guangxi Zhuang Autonomous Region.

In 1973, virologist Zeng Yi revealed a link between NPC and Epstein-Barr virus infection. This was met with some controversy as direct proof of the connection has remained elusive.

But with cancer becoming the number one killer in the country in 2005, the Chinese government is willing to back a US$1.2 million one-year trial of a preventative vaccine for Epstein-Barr virus. If successful, the vaccine will be administered to 300 volunteers.

The trial has been met with some criticism, with scientists claiming that such a large-scale vaccination is "economically unjustified".

A safety trial in 30 patients is planned for the end of this year.

Link to full article in Science

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.